Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01448213
Other study ID # 2011-0329
Secondary ID
Status Completed
Phase Phase 2
First received October 4, 2011
Last updated August 22, 2014
Start date October 2011
Est. completion date January 2014

Study information

Verified date August 2014
Source Price Vision Group
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery. The investigators hope to determine if one is more effective at preventing rejection or if both are equally effective.


Description:

Graft rejection is one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used after transplant surgery. The steroid eye drop dosing regimen varies from surgeon to surgeon, because no studies have been done to determine the optimum dosing regimen.


Recruitment information / eligibility

Status Completed
Enrollment 264
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility INCLUSION CRITERIA: The following are requirements for inclusion in the study:

- Male or female patient, at least 18 years of age, who is a candidate for DMEK due to corneal endothelial dysfunction or who has undergone DMEK within the last 7 weeks

- Patient is able and willing to administer eye drops.

- Patient is able to comprehend and has signed the Informed Consent form.

- Patient is likely to complete the entire one-year course of the study.

- Patient has best corrected visual acuity (BCVA) of at least 20/200 in the fellow eye.

- Corneal neovascularization will not be judged as an exclusion criteria for the study

EXCLUSION CRITERIA: The following are exclusion criteria for patients in this study:

- A patient with a previous failed graft in the study eye with a history of a prior rejection episode

- A patient exhibiting any intraocular inflammation

- A patient with a known sensitivity to any of the ingredients in the study medications

- A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study

- A patient with abnormal eyelid function

- A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis

- A patient with the presence of any ocular disease that would interfere with the evaluation of the study treatment

- A patient with a history of non-compliance with using prescribed medication

- A patient who is concurrently involved in or participated in another clinical trial within 30 days prior to enrollment in this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention


Intervention

Drug:
Prednisolone acetate
Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
Fluorometholone
Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.

Locations

Country Name City State
Germany University of Erlangen Erlangen
United States Price Vision Group Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Price Vision Group

Countries where clinical trial is conducted

United States,  Germany, 

References & Publications (1)

Price MO, Price FW Jr, Kruse FE, Bachmann BO, Tourtas T. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Cornea. 2014 Sep;33(9):880-6. doi: 10.1097/IC — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Eyes With Immunologic Graft Rejection Episodes Within 1 year Yes
Secondary Number of Eyes With Intraocular Pressure (IOP) Elevation Absolute IOP greater than or equal to 24 mm Hg or a relative increase of 10 mm Hg over the baseline preoperative reading. one day, two days, one week, one month, 3 months, 6 months and 12 months after DMEK Yes
See also
  Status Clinical Trial Phase
Completed NCT03248037 - Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation Phase 3
Enrolling by invitation NCT05956535 - Air Optix® Night and Day® Aqua Therapeutic Wear
Recruiting NCT02020044 - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) N/A
Recruiting NCT03407755 - Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK) N/A
Completed NCT03450954 - Long Term Results of Amniotic Membrane Transplant in Bullous Keratopathy Patients N/A
Completed NCT01926535 - Amniotic Membrane Graft In Syntomathic Bullous Keratopathy Phase 2
Completed NCT01106274 - The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy N/A
Completed NCT03763721 - The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation N/A
Completed NCT05891106 - AONDA Therapeutic Indication Study I
Active, not recruiting NCT04894110 - Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema Phase 1
Completed NCT00659308 - Amniotic Membrane and Anterior Stromal Puncture to the Treatment of Symptomatic Bullous Keratopathy N/A
Completed NCT01122043 - The SNEC DSAEK EndoGlide Clinical Trial N/A
Completed NCT00800111 - Study of Endothelial Keratoplasty Outcomes N/A
Recruiting NCT05636579 - Study to Assess Safety and Tolerability of Multiple Doses of EO2002 Phase 1
Recruiting NCT04319848 - Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty Phase 1
Recruiting NCT05436665 - The Belgian Endothelial Surgical Transplant of the Cornea N/A
Not yet recruiting NCT02736877 - Corneal Transplantation Guided by OCT RESCAN N/A

External Links